TY - JOUR
T1 - Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease
AU - Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP)
AU - Yu, Alan S.L.
AU - Shen, Chengli
AU - Landsittel, Douglas P.
AU - Grantham, Jared J.
AU - Cook, Larry T.
AU - Torres, Vicente E.
AU - Chapman, Arlene B.
AU - Bae, Kyongtae Ty
AU - Mrug, Michal
AU - Harris, Peter C.
AU - Rahbari-Oskoui, Frederic F.
AU - Shi, Tiange
AU - Bennett, William M.
N1 - Funding Information:
The CRISP study is supported by cooperative agreements from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (DK056943, DK056956, DK056957, and DK056961), and by R01 DK113111. This study was also supported in part by the National Institute of Diabetes and Digestive and Kidney Diseases through P30 grants to the Kansas PKD Research and Translation Core Center (DK106912) and the Mayo Translational PKD Center (DK090728), by the National Center for Research Resources General Clinical Research Centers at each institution (RR000039, Emory University; RR00585, Mayo College of Medicine; RR23940, Kansas University Medical Center; and RR000032, University of Alabama at Birmingham), and the National Center for Advancing Translational Sciences Clinical and Translational Science Awards at each institution (RR025008 and TR000454, Emory; RR024150 and TR000135, Mayo College of Medicine; RR033179 and TR000001, Kansas University Medical Center; RR025777, TR000165, and TR001417, University of Alabama at Birmingham; and RR024153 and TR000005, University of Pittsburgh School of Medicine). The investigators are indebted to the study coordinators in CRISP.
Funding Information:
ASLY is a consultant for Regulus Therapeutics. VET is a member of the steering committees for the TEMPO and REPRISE clinical trials, has received research support from Otsuka Pharmaceutical, and is a consultant for Vertex, Sanofi, and Palladio. PCH has received research funding from Otsuka Pharmaceuticals. MM is a consultant for Otsuka and Sanofi and has received research support from Otsuka Pharmaceuticals and Sanofi. FFR-O is a consultant for Keryx and Kadmon and has received research funding from Otsuka, Kadmon, and Genzyme. ABC is a consultant for Otsuka, Pfizer, and Sanofi and has received research funding from Boston Scientific, Kadmon, and Otsuka. All the other authors declared no competing interests.
Publisher Copyright:
© 2019 International Society of Nephrology
PY - 2019/5
Y1 - 2019/5
N2 - Autosomal dominant polycystic kidney disease (ADPKD) is characterized by cyst and kidney growth, which is hypothesized to cause loss of functioning renal mass and eventually end-stage kidney disease. However, the time course of decline in glomerular filtration rate (GFR) is poorly defined. The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease study is a 14-year observational cohort study of 241 adults with ADPKD. As an estimate of the rate of kidney growth, participants were stratified into 5 subclasses based on baseline age and magnetic resonance imaging measurements of total kidney volume (TKV) according to the method of Irazabal. GFR trajectories spanning over four decades of life were reconstructed and fitted using mixed polynomial models, which were validated using data from the HALT-PKD study. GFR trajectories were nonlinear, with a period of relative stability in most participants, followed by accelerating decline. The shape and slope of these trajectories were strongly associated with baseline Irazabal class. Patients with PKD1 mutations had a steeper GFR decline than patients with PKD2 mutations or with no detected mutation, largely mediated by the effect of genotype on Irazabal class. Thus, GFR decline in ADPKD is nonlinear, and its trajectory throughout adulthood can be predicted from a single measurement of kidney volume. These models can be used for clinical prognostication, clinical trial design, and patient selection for clinical interventions. Our findings support a causal link between growth in kidney volume and GFR decline, adding support for the use of TKV as a surrogate endpoint in clinical trials.
AB - Autosomal dominant polycystic kidney disease (ADPKD) is characterized by cyst and kidney growth, which is hypothesized to cause loss of functioning renal mass and eventually end-stage kidney disease. However, the time course of decline in glomerular filtration rate (GFR) is poorly defined. The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease study is a 14-year observational cohort study of 241 adults with ADPKD. As an estimate of the rate of kidney growth, participants were stratified into 5 subclasses based on baseline age and magnetic resonance imaging measurements of total kidney volume (TKV) according to the method of Irazabal. GFR trajectories spanning over four decades of life were reconstructed and fitted using mixed polynomial models, which were validated using data from the HALT-PKD study. GFR trajectories were nonlinear, with a period of relative stability in most participants, followed by accelerating decline. The shape and slope of these trajectories were strongly associated with baseline Irazabal class. Patients with PKD1 mutations had a steeper GFR decline than patients with PKD2 mutations or with no detected mutation, largely mediated by the effect of genotype on Irazabal class. Thus, GFR decline in ADPKD is nonlinear, and its trajectory throughout adulthood can be predicted from a single measurement of kidney volume. These models can be used for clinical prognostication, clinical trial design, and patient selection for clinical interventions. Our findings support a causal link between growth in kidney volume and GFR decline, adding support for the use of TKV as a surrogate endpoint in clinical trials.
KW - ADPKD
KW - chronic kidney disease
UR - http://www.scopus.com/inward/record.url?scp=85063250968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063250968&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2018.12.023
DO - 10.1016/j.kint.2018.12.023
M3 - Article
C2 - 30922668
AN - SCOPUS:85063250968
SN - 0085-2538
VL - 95
SP - 1253
EP - 1261
JO - Kidney international
JF - Kidney international
IS - 5
ER -